The AGO Study Group is a non-profit organisation with the aim to enhance the therapy of pelvic tumours in women. It developed from the AGO Ovarian Cancer Study Group, which was founded in 1993.
Ovar
Primary diseas
AGO-OVAR 10
Phase III trial
A randomized, double blind, placebo controlled, multicenre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapie.
Phase III trial
A randomized, double blind, placebo controlled, multicenre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapie.
AGO-OVAR 15
Phase II trial
An open-label, multicentre, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for first-line treatment of patients with epithelial ovarian cancer FIGO stages IIb - IV.
Phase II trial
An open-label, multicentre, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for first-line treatment of patients with epithelial ovarian cancer FIGO stages IIb - IV.
ICON7/AGO-OVAR 11
Phase III trial
A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.
Ovar
Primary diseas
AGO-OVAR 16 / VEG1100655
Phase III trial
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AGO-OVAR 9
Phase III trial
A multi-national randomized Phase III GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelial ovarian cancer FIGO stages I – IV.
Phase III trial
A multi-national randomized Phase III GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelial ovarian cancer FIGO stages I – IV.
AGO-OVAR 2.10
Phase IIa trial
Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody removab® (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients.
Phase IIa trial
Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody removab® (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients.
AGO-OVAR 2.11
Phase II trial
A randomized multicentre trial with SU11248 to evaluate dosage, schedule, tolerability, toxicity and effectiveness of al multitargeted receptor tyrosine kinase inhibitor monotherapie.
Phase II trial
A randomized multicentre trial with SU11248 to evaluate dosage, schedule, tolerability, toxicity and effectiveness of al multitargeted receptor tyrosine kinase inhibitor monotherapie.
CALYPSO/AGO-OVAR 2.9
Phase III trial
A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX®) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months).
Phase III trial
A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX®) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months).
AGO-OVAR 2.7
Phase III trial
Reinduktionstherapie mit Paclitaxel und Carboplatin plus Epoetin Alfa versus Reinduktionstherapie mit Paclitaxel und Carboplatin beim rezidivierenden platinsensiblen Ovarialkarzinom.
Phase III trial
Reinduktionstherapie mit Paclitaxel und Carboplatin plus Epoetin Alfa versus Reinduktionstherapie mit Paclitaxel und Carboplatin beim rezidivierenden platinsensiblen Ovarialkarzinom.
AGO-OVAR 2.3
Phase III trial
Topotecan versus Treosulfan in der Rezidivtherapie von Patientinnen mit Ovarialkarzinom nach Platin-/Paclitaxelvorbehandlung.
Phase III trial
Topotecan versus Treosulfan in der Rezidivtherapie von Patientinnen mit Ovarialkarzinom nach Platin-/Paclitaxelvorbehandlung.
Uterus
AGO GYN 4
Phase I trial
A phase I open label dose escalation study of oral treatment with BIBF 1120 in combination with standard treatment of paclitaxel and carboplatin in patients with advanced gynaecological malignancies.
Phase I trial
A phase I open label dose escalation study of oral treatment with BIBF 1120 in combination with standard treatment of paclitaxel and carboplatin in patients with advanced gynaecological malignancies.
AGO GYN 5
Phase II trial
Efficacy and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors.
Phase II trial
Efficacy and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors.
AGO GYN 6
Phase I/II trial
Feasibility Study of Pazopanib in Combination With Chemo in Gyn Tumors.
Phase I/II trial
Feasibility Study of Pazopanib in Combination With Chemo in Gyn Tumors.
AGO GYN 7
Klinische Prüfung der Phase II
Einsatz der Kombinationschemotherapie PegLiposomales Doxorubicin (PLD) und Carboplatin bei gynäkologischen Sarkomen und gemischt-mesenchymalen Tumoren.
Klinische Prüfung der Phase II
Einsatz der Kombinationschemotherapie PegLiposomales Doxorubicin (PLD) und Carboplatin bei gynäkologischen Sarkomen und gemischt-mesenchymalen Tumoren.
Clinical trials in surgical settings
AGO-OVAR OP.2/DESKTOP II
Validation of a score of predictive factors for complete resection in paltium-sensitive ovarian cancer.
Validation of a score of predictive factors for complete resection in paltium-sensitive ovarian cancer.